Jump to content

Cancer immunotherapy

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 69.176.216.130 (talk) at 21:27, 10 August 2010 (→External links: updated Cancer Vaccine Consortium -- name changed in March 2010 to Cancer Immunotherapy Consortium; Web site URL updated to new landing page.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cancer immunotherapy is the use of the immune system to reject cancer. The main premise is stimulating the patient's immune system to attack the malignant tumor cells that are responsible for the disease. This can be either through immunization of the patient (eg. by administering a cancer vaccine, such as Dendreon's Provenge), in which case the patient's own immune system is trained to recognize tumor cells as targets to be destroyed, or through the administration of therapeutic antibodies as drugs, in which case the patient's immune system is recruited to destroy tumor cells by the therapeutic antibodies.

Since the immune system responds to the environmental factors it encounters on the basis of discrimination between self and non-self, many kinds of tumor cells that arise as a result of the onset of cancer are more or less tolerated by the patient's own immune system since the tumor cells are essentially the patient's own cells that are growing, dividing and spreading without proper regulatory control.

In spite of this fact, however, many kinds of tumor cells display unusual antigens that are either inappropriate for the cell type and/or its environment, or are only normally present during the organisms' development (e.g. fetal antigens). Examples of such antigens include the glycosphingolipid GD2, a disialoganglioside that is normally only expressed at a significant level on the outer surface membranes of neuronal cells, where its exposure to the immune system is limited by the blood-brain barrier. GD2 is expressed on the surfaces of a wide range of tumor cells including neuroblastoma, medulloblastomas, astrocytomas, melanomas, small-cell lung cancer, osteosarcomas and other soft tissue sarcomas. GD2 is thus a convenient tumor-specific target for immunotherapies.

Other kinds of tumor cells display cell surface receptors that are rare or absent on the surfaces of healthy cells, and which are responsible for activating cellular signal transduction pathways that cause the unregulated growth and division of the tumor cell. Examples include ErbB2, a constitutively active cell surface receptor that is produced at abnormally high levels on the surface of breast cancer tumor cells.

Monoclonal antibody therapy

Main article: Monoclonal antibody therapy

Antibodies are a key component of the adaptive immune response, playing a central role in both in the recognition of foreign antigens and the stimulation of an immune response to them. It is not surprising therefore, that many immunotherapeutic approaches involve the use of antibodies. The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens such as the unusual antigens that are presented on the surfaces of tumors.

A number of therapeutic monoclonal antibodies have been approved for use in humans; approvals mentioned here are by the U.S. Food and Drug Administration (FDA).

Cancer immunotherapy:Monoclonal antibodies[1]
Antibody Brand name Approval date Type Target Approved treatment(s)
Alemtuzumab Campath 2001 humanized CD52 Chronic lymphocytic leukemia
Bevacizumab Avastin 2004 humanized vascular endothelial growth factor colorectal cancer
Cetuximab Erbitux 2004 chimeric epidermal growth factor receptor colorectal cancer
Gemtuzumab ozogamicin Mylotarg 2000 humanized CD33 acute myelogenous leukemia (with calicheamicin)
Ibritumomab tiuxetan Zevalin 2002 murine CD20 non-Hodgkin lymphoma (with yttrium-90 or indium-111)
Panitumumab Vectibix 2006 human epidermal growth factor receptor colorectal cancer
Rituximab Rituxan, Mabthera 1997 chimeric CD20 non-Hodgkin lymphoma
Trastuzumab Herceptin 1998 humanized ErbB2 breast cancer

Alemtuzumab

Alemtuzumab is an anti-CD52 humanized IgG1 monoclonal antibody indicated for the treatment of Chronic lymphocytic leukemia(CLL), the most frequent form of leukaemia in Western countries.[2] The function of CD52 is unknown, but it is found on >95% of peripheral blood lymphocytes and monocytes. Upon binding to CD52, alemtuzumab initiates its cytotoxic effect by complement fixation and antibody-dependent cell-mediated cytotoxicity mechanisms. Alemtuzumab therapy is also indicated for T-prolymphocytic leukaemia (TPPL), for which no standard treatment exists. This is a highly aggressive tumour, with a median survival of 7.5 months.[3]

Bevacizumab

Bevacizumab is a humanized IgG1 monoclonal antibody which binds to and sterically interferes with the vascular endothelial growth factor-A (VEGF-A), preventing receptor activation. A marked increase in VEGF expression is thought to play a role in tumor angiogenesis. Bevacizumab is indicated for colon cancer; but has been applied to numerous other cancers in small scale studies, especially renal cell carcinoma. Results obtained showed that bevacizumab increased the duration of survival, progression-free survival, the rate of response and the duration of response in a statistically relevant manner.[4]

Cetuximab

Cetuximab is a chimeric IgG1 monoclonal antibody which targets the extracellular domain of the epidermal growth factor receptor (EGFR). It functions by competitively inhibiting ligand binding, thereby preventing EGFR activation, and is indicated for the treatment of colorectal cancer. Studies have also been carried out on numerous other malignancies, especially non-small cell lung cancer and head and neck cancer. As a single agent, cetuximab showed a response rate of 10.8% in patients with EGFR overexpressed metastatic colon cancer.[1] Other anti-EGFR monoclonal antibodies in development include: ABX-EGF, hR3, and EMD 72000. Although they hold significant promise for the future, as of yet none of the agents are currently beyond phase I clinical trials.

Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is an “immuno-conjugate” of an anti-CD33 antibody chemically linked to calicheamicin, a cytotoxic agent. It is indicated for the treatment of acute myeloid leukaemia (AML). The patient group most likely to benefit from gemtuzumab is young adults, and trials have reported high complete responses (85%), when combined with intensive chemotherapy. There are minimal side-effects associated with Gemtuzumab therapy.[5]

Rituximab

Rituximab is a chimeric monoclonal antibody specific for CD20. CD20 is widely expressed on B-cells. Although the function of CD20 is relatively unknown it has been suggested that CD20 could play a role in calcium influx across plasma membrane, maintaining intracellular calcium concentration and allowing for the activation of B cells.[6] The exact mode of action of rituximab is also unclear, but it has been found to have a general regulatory effect on the cell cycle and on immune-receptor expression.[1] Experiments involving primates showed that treatment with anti-CD20 reduced peripheral B-cells by 98%, and peripheral lymph node and bone marrow B-cells by up to 95%.[7]

Trastuzumab

Trastuzumab is a monoclonal IgG1 humanized antibody specific for the epidermal growth factor receptor 2 protein (HER2). It received FDA-approval in 1998, and is clinically used for the treatment of breast cancer. The use of Trastuzumab is restricted to patients whose tumours over-express HER-2, as assessed by immunohistochemistry (IHC) and either chromogenic or Fluorescent in situ hybridisation (FISH), as well as numerous PCR-based methodologies.

HER-2 is a member of the epidermal growth factor receptor (EGFR) family of transmembrane tyrosine kinases, and is normally involved in regulation of cell proliferation and differentiation.[8] Amplification or overexpression of HER-2 is present in 25-30% of breast carcinomas and has been associated with aggressive tumour phenotype, poor prognosis, non-responsiveness to hormonal therapy and reduced sensitivity to conventional chemotherapeutic agents.[9]

Radioimmunotherapy

Radioimmunotherapy involves the use of radioactively conjugated murine antibodies against cellular antigens. Most research currently involved their application to lymphomas, as these are highly radio-sensitive malignancies. To limit radiation exposure, murine antibodies were especially chosen, as their high immunogenicity promotes rapid clearance from the body.

Ibritumomab tiuxetan

Ibritumomab tiuxetan is a murine antibody chemically linked to a chelating agent which binds yttrium-90. 90Y is a beta radiator, has a half-life of 64 h and a tissue penetration of 1-5 millimetres. Its use has been investigated, primarily in the treatment of follicular lymphoma.[10]

Tositumomab/iodine (131I) tositumomab regimen

Tositumomab is a murine IgG2a anti-CD20 antibody. Iodine (131I) tositumomab is covalently bound to Iodine 131. 131I emits both beta and gamma radiation, and is broken down rapidly in the body.[11] Clinical trials have established the efficacy of a sequential application of tositumomab and iodine (131I) tositumomab in patients with relapsed follicular lymphoma.[12]

Advances in immunotherapy

The development and testing of second generation immunotherapies are already under way. While antibodies targeted to disease-causing antigens can be effective under certain circumstances, in many cases, their efficacy may be limited by other factors. In the case of cancer tumors, the microenvironment is immunosuppressive, allowing even those tumors that present unusual antigens to survive and flourish in spite of the immune response generated by the cancer patient, against his or her own tumor tissue. Certain members of a group of molecules known as cytokines, such as Interleukin-2 also play a key role in modulating the immune response, and have been tried in conjunction with antibodies in order to generate an even more devastating immune response against the tumor. While the therapeutic administration of such cytokines may cause systemic inflammation, resulting in serious side effects and toxicity, a new generation of chimeric molecules consisting of an immune-stimulatory cytokine attached to an antibody that targets the cytokine's activity to a specific environment such as a tumor, are able to generate a very effective yet localized immune response against the tumor tissue, destroying the cancer-causing cells without the unwanted side-effects. A different type of chimeric molecule is an artificial T cell receptor.

The targeted delivery of cytokines by anti-tumor antibodies is one example of using antibodies to delivery payloads rather than simply relying on the antibody to trigger an immune response against the target cell. Another strategy is to deliver a lethal radioactive dose directly to the target cell, which has been utilized in the case of the Zevalin therapeutic. A third strategy is to deliver a lethal chemical dose to the target, as used in the Mylotarg therapeutic. Engineering the antibody-payload pair in such a way that they separate after entry into a cell by endocytosis can potentially increase the efficacy of the payload. One strategy to accomplish this is the use of a disulfide linkage which could be severed by the reducing conditions in the cellular interior. However, recent evidence suggests that the actual intracellular trafficking of the antibody-payload after endocytosis is such to make this strategy not generally applicable. Other potentially useful linkage types include hydrazone and peptide linkages.[13]

Latest research

In 2001, two U.S. based non-profit organizations, the Cancer Research Institute and the Ludwig Institute for Cancer Research, formed the Cancer Vaccine Collaborative, a unique global network of clinical trial sites with special expertise in immunology, built to centrally design and coordinate early-stage clinical trials to be run in parallel in order to identify more quickly the optimal combination of reagents, or vaccine components, necessary for a successful therapeutic cancer vaccine. The Cancer Vaccine Collaborative has to-date (June 2009) completed or is currently running more than 40 clinical trials of different therapeutic cancer vaccines, including 37 phase I, 6 phase II, and 1 fully-randomized phase II clinical trials, and has published more than 130 scientific papers in peer-reviewed journals. Nearly all of these trials featured vaccines targeting various forms of the cancer-testes antigen, NY-ESO-1, a highly-immunogenic, prototypical protein marker limited in expression to a wide variety of cancer types but not in normal tissue, with the exception of the immune-privileged testes. Vaccines tested in Cancer Vaccine Collaborative trials have induced integrated immune responses composed of target-specific antibodies and CD4+ and CD8+ T lymphocytes, all of which are held to be essential for effective long-term control of cancer. Insights from these trials have generated a strong framework for the selection of components that will likely comprise an ideal therapeutic cancer vaccine, including: multiple cancer-antigens in various forms delivered with potent adjuvants and all administered in a prime-boost setting in conjunction with a modulator of cancer immunosuppression.

In June 2008, it was announced that US doctors from the Clinical Research Division led by Cassian Yee at Fred Hutchinson Cancer Research Center in Seattle have for the first time successfully treated a skin cancer patient by using immune cells cloned from his own immune system which were then re-injected into him. The patient, who was suffering from advanced skin cancer, was free from tumours within eight weeks of being injected with billions of his own immune cells in the first case of its kind. Experts say that this case could be a landmark in the treatment of cancer in general. Larger trials are now under way. [1]

More new research is being conducted by Drs. Richard O'Reilly and Michel Sadelain. Drs. O'Reilly and Sadelain have done extensive research at Memorial Sloan-Kettering Cancer Center hospital and are among leaders of the cancer adoptive Immunotherapy field[14]

Topical immunotherapy

Dermatologists use new creams and injections in the management of benign and malignant skin tumors. Topical immunotherapy utilizes an immune enhancement cream (imiquimod) which is an interferon producer causing the patient's own killer T cells to destroy warts, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, cutaneous T cell lymphoma, and Superficial spreading melanoma. Injection immunotherapy uses mumps, candida or trichophytin antigen injections to treat warts (HPV induced tumors).

Natural products

Main article: Medicinal mushrooms

Some types of natural products have shown promise to stimulate the immune system. Research suggests that mushrooms like Reishi and Agaricus blazei may be able to stimulate the immune system. Research has shown that Agaricus blazei may be a potent stimulator of natural killer cells.[15] Agaricus blazei is rich in proteoglucans and beta-glucans, which are potent stimulators of macrophages.[16]

Research ss the compounds in medicinal mushrooms most responsible for up-regulating the immune system and providing an anti-cancer effect, are a diverse collection of polysaccharide compounds, particularly beta-glucans. Beta-glucans are known as "biological response modifiers", and their ability to activate the immune system is well documented. Specifically, beta-glucans stimulate the innate branch of the immune system. Research has shown beta-glucans have the ability to stimulate macrophage, NK cells, T cells, and immune system cytokines. The mechanisms in which beta-glucans stimulate the immune system is only partially understood. One mechanism in which beta-glucans are able to activate the immune system, is by interacting with the Macrophage-1 antigen (CD18) receptor on immune cells.[17]

Highly purified compounds isolated from medicinal mushrooms such as lentinan (isolated from Shiitake), and Polysaccharide-K, (isolated from Trametes versicolor), have become incorporated into the health care system of a few countries, such as Japan.[18] Japan's Ministry of Health, Labour and Welfare approved the use of Polysaccharide-K in the 1980s, to stimulate the immune systems of patients undergoing chemotherapy. In Australia, a pharmaceutical based on a mixture of several mycological extracts including lentinan and Polysaccharide-K is sold commercially as MC-S.

See also

References

  1. ^ a b c Waldmann, Thomas A. (2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–277. doi:10.1038/nm0303-269. PMID 12612576.
  2. ^ Byrd JC, Stilgenbauer S, Flinn IW. Chronic Lymphocytic Leukemia. Hematology (Am Soc Hematol Educ Program) 2004: 163-183. Date retrieved: 26/01/2006.
  3. ^ Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20: 205-213.
  4. ^ Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.
  5. ^ De Angelo D, Stone R, Durant S, et al. Gemtuzumab ozogamicin (Mylotarg) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: Two age-specific phase 2 trials. Blood 2003; 102: 100a [abstract].
  6. ^ Janeway, Charles (2001). Immunobiology; Fifth Edition. New York and London: Garland Science. ISBN 0-8153-4101-6. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help).
  7. ^ Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
  8. ^ Jones FE, Stern DF. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development. Oncogene 1999; 18: 3481-3490.
  9. ^ Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
  10. ^ Shipley DL, Spigel DR, Carrell DL, Dannaher C, Greco FA, Hainsworth JD. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2004; 22: 6519 [abstract].
  11. ^ Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for Non-Hodgkin’s Lymphoma. Clin Med Res 2005; 3: 157-165.
  12. ^ Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449.
  13. ^ Austin C.D.; et al. (2005). "Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates". Proc Natl Acad Sci U S A. 102 (50): 17987–17992. doi:10.1073/pnas.0509035102. PMC 1298180. PMID 16322102. {{cite journal}}: Explicit use of et al. in: |author= (help)
  14. ^ http://www.mskcc.org/mskcc/html/86755.cfm
  15. ^ Amino, M; Noguchi, R; Yata, J; Matsumura, J; Hirayama, R; Abe, O; Enomoto, K; Asato, Y (1983). "STUDIES ON THE EFFECT OF LENTINAN ON HUMAN IMMUNE SYSTEM. II. IN VIVO EFFECT ON NK ACTIVITY, MLR INDUCED KILLER ACTIVITY AND PHA INDUCED BLASTIC RESPONSE OF LYMPHOCYTES IN CANCER PATIENTS". Gan to Kagaku Ryoho. 10 (9): 2000–6. PMID 6225393. {{cite journal}}: line feed character in |title= at position 97 (help)
  16. ^ Hetland, G; Sandven, P (2002). "b-1,3-glucan reduces growth of Mycobacterium bovis in macrophage cultures". FEMS Immunol Med Microbiol. 33 (1): 41–45. PMID 11985967. {{cite journal}}: line feed character in |title= at position 45 (help)
  17. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15084502, please use {{cite journal}} with |pmid=15084502 instead. (review)
  18. ^ "Coriolus Versicolor".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cancer_immunotherapy&oldid=378249392"